Citations

Clear

477 citation(s) found for "Wallace, AM".

413.1: The Impact of UNOS Acuity Circles-Based Organ Allocation on DCD Liver Transplant Rates and Waitlist Mortality in the United States
Wallace, David , Burdine, Lyle , Patel, Raj , Rude, Mary K., Balong, Julius, Wells, Allison Childs, Krinock, Derek , Singer, Andrew L., Mathur, Amit K. , Giorgakis, Emmanouil , Ivanics, Tommy , Wells, Allison, Hardgrave, Hailey

Mayo Clinic

Transplantation | September 19, 2022 | Volume: 106 | Issue: 9S | Pages: S409-S409

10.1097/01.tp.0000887652.80903.2e Get It

To register and report is good for the science of endoscopy
Wallace, Michael B. , Kinnan, Stephanie , Wallace, Michael B

Mayo Clinic

Endoscopy | September 16, 2022 | Volume: 55 | Issue: 01 | Pages: 42-43

10.1055/a-1929-1600 | PMID 36113490 Get It

Prolonged COVID-19 symptom duration in people with systemic autoimmune rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey
DiIorio, Michael , Kennedy, Kevin , Putman, Michael , Sirotich, Emily , Sattui, Sebastian E. , Foster, Gary , Harrison, Carly , Larché, Maggie , Levine, Mitchell , Moni, Tarin T , Thabane, Lehana , Bhana, Suleman , Costello, Wendy, Grainger, Rebecca , Machado, Pedro , Sufka, Paul , Wallace, Zachary S. , Gore‐Massy, Monique , Kodhek, More A, Lalonde, Nadine, Tomasella, Laura-Ann, Wallace, John, Akpabio, Akpabio , Alpizar-Rodriguez, D. , Berenbaum, Françis , Buliņa, Inita , Chock, Eugenia Yupei , Duff, Eimear , Hsieh, Evelyn , Kibbi, Lina El, Liew, David , Lo, Chieh , Nudel, Michal, Singh, Aman Dev , Hausmann, Jonathan S. , Sparks, Jeffrey A. , Putman, Michael S , Sirotich, Emily , Sattui, Sebastian E , Machado, Pedro M , Robinson, Philip C , Akpabio, Akpabio , Alpízar-Rodríguez, Deshiré , Berenbaum, Francis , Chock, Eugenia Yupei , Liew, David Fl , Singh, Jasvinder A , Ugarte-Gil, Manuel F , Hausmann, Jonathan S , Simard, Julia F , Sparks, Jeffrey A , Grainger, Rebecca , Hsieh, Evelyn , Thabane, Lehana , Kennedy, Kevin , Liew, Jean W. , Robinson, Philip C. , Yazdany, Jinoos , Howard, Richard A, Wallace, John, Beesley, Richard P. , Conway, Richard , Duarte‐García, Alí , Gheita, Tamer A. , Graef, Elizabeth R. , Singh, Jasvinder A. , Singh, Namrata , Ugarte‐Gil, Manuel F.

Mayo Clinic

RMD Open | September 14, 2022 | Volume: 8 | Issue: 2 | Pages: e002587

10.1136/rmdopen-2022-002587 | PMID 36104117 Get It

Objective We investigated prolonged COVID-19 symptom duration, defined as lasting 28 days or longer, among people with systemic autoimmune rheumatic diseases (SARDs). Methods We analysed data from the COVID-19 Global Rheumatology Alliance Vaccine Survey (2 April 2021–15 October 2021) to identify people with SARDs reporting test-confirmed COVID-19. Participants reported COVID-19 severity and symptom duration, sociodemographics and clinical characteristics. We reported the proportion experiencing prolonged symptom duration and investigated associations with baseline characteristics using logistic regression. Results We identified 441 respondents with SARDs and COVID-19 (mean age 48.2 years, 83.7% female, 39.5% rheumatoid arthritis). The median COVID-19 symptom duration was 15 days (IQR 7, 25). Overall, 107 (24.2%) respondents had prolonged symptom duration (≥28 days); 42/429 (9.8%) reported symptoms lasting ≥90 days. Factors associated with higher odds of prolonged symptom duration included: hospitalisation for COVID-19 vs not hospitalised and mild acute symptoms (age-adjusted OR (aOR) 6.49, 95% CI 3.03 to 14.1), comorbidity count (aOR 1.11 per comorbidity, 95% CI 1.02 to 1.21) and osteoarthritis (aOR 2.11, 95% CI 1.01 to 4.27). COVID-19 onset in 2021 vs June 2020 or earlier was associated with lower odds of prolonged symptom duration (aOR 0.42, 95% CI 0.21 to 0.81). Conclusion Most people with SARDs had complete symptom resolution by day 15 after COVID-19 onset. However, about 1 in 4 experienced COVID-19 symptom duration 28 days or longer; 1 in 10 experienced symptoms 90 days or longer. Future studies are needed to investigate the possible relationships between immunomodulating medications, SARD type/flare, vaccine doses and novel viral variants with prolonged COVID-19 symptoms and other postacute sequelae of COVID-19 among people with SARDs.
Neural Transformers for Intraductal Papillary Mucosal Neoplasms (IPMN) Classification in MRI images
Salanitri, Federica Proietto , Bellitto, Giovanni , Irmakci, Ismail , Wallace, Michael B. , Bolan, Candice W. , Engels, Megan , Hoogenboom, Sanne, Wallace, Michael B , Palazzo, Simone , Aldinucci, Marco , Bağcı, Ulaş , Giordano, D., Spampinato, Concetto

Mayo Clinic

2022 44th Annual International Conference of the IEEE Engineering in Medicine & Biology Society (EMBC) | September 8, 2022 | Volume: No volume available | Issue: No issue available | Pages: 475-479

10.1109/embc48229.2022.9871547 | PMID 36085787 Get It

Association of Residual Ductal Carcinoma In Situ With Breast Cancer Recurrence in the Neoadjuvant I-SPY2 Trial
Osdoit, Marie , Symmans, W. Fraser , Ewing, Cheryl A. , Chen, Yunn‐Yi , Krings, Gregor , Zare, Somaye , Fadare, Oluwole , Lancaster, Rachael, Wei, Shi , Godellas, Constantine , Tang, Ping , Klein, Molly, Sahoo, Sunati , Carter, Jodi M. , Chen, Beiyun, Ahrendt, Gretchen , Tchou, Julia , Tousimis, Eleni A. , Zeck, Jay , Jaskowiak, Nora , Sattar, Husain, Naik, Arpana, Rosa, Marilin , Khazai, Laila , Rendi, Mara H. , Lang, Julie E. , Lu, Janice , Tawfik, Ossama , Asare, Smita , Symmans, W Fraser , Carter, Jodi , Yau, Christina , Boughey, Judy C. , Balassanian, Ronald , Wallace, Anne M. , Tuttle, Todd M. , Hieken, Tina J. , Feldman, Michael D. , Lee, Marie Catherine , Esserman, Laura J. , Mukhtar, Rita A.

Mayo Clinic

JAMA Surgery | September 7, 2022 | Volume: 157 | Issue: 11 | Pages: 1034

10.1001/jamasurg.2022.4118 | PMID 36069821 Get It

ImportancePathologic complete response (pCR) after neoadjuvant chemotherapy (NAC) in breast cancer strongly correlates with overall survival and has become the standard end point in neoadjuvant trials. However, there is controversy regarding whether the definition of pCR should exclude or permit the presence of residual ductal carcinoma in situ (DCIS).ObjectiveTo examine the association of residual DCIS in surgical specimens after neoadjuvant chemotherapy for breast cancer with survival end points to inform standards for the assessment of pathologic complete response.Design, Setting, and ParticipantsThe study team analyzed the association of residual DCIS after NAC with 3-year event-free survival (EFS), distant recurrence-free survival (DRFS), and local-regional recurrence (LRR) in the I-SPY2 trial, an adaptive neoadjuvant platform trial for patients with breast cancer at high risk of recurrence. This is a retrospective analysis of clinical specimens and data from the ongoing I-SPY2 adaptive platform trial of novel therapeutics on a background of standard of care for early breast cancer. I-SPY2 participants are adult women diagnosed with stage II/III breast cancer at high risk of recurrence.InterventionsParticipants were randomized to receive taxane and anthracycline-based neoadjuvant therapy with or without 1 of 10 investigational agents, followed by definitive surgery.Main Outcomes and MeasuresThe presence of DCIS and EFS, DRFS, and LRR.ResultsThe study team identified 933 I-SPY2 participants (aged 24 to 77 years) with complete pathology and follow-up data. Median follow-up time was 3.9 years; 337 participants (36%) had no residual invasive disease (residual cancer burden 0, or pCR). Of the 337 participants with pCR, 70 (21%) had residual DCIS, which varied significantly by tumor-receptor subtype; residual DCIS was present in 8.5% of triple negative tumors, 15.6% of hormone-receptor positive tumors, and 36.6% of ERBB2-positive tumors. Among those participants with pCR, there was no significant difference in EFS, DRFS, or LRR based on presence or absence of residual DCIS.Conclusions and RelevanceThe analysis supports the definition of pCR as the absence of invasive disease after NAC regardless of the presence or absence of DCIS.Trial RegistrationClinicalTrials.gov Identifier NCT01042379.
Characteristics and Outcomes of People With Gout Hospitalized Due to COVID‐19: Data From the COVID‐19 Global Rheumatology Alliance Physician‐Reported Registry
Jatuworapruk, Kanon , Montgomery, Anna , Conway, Richard , Durcan, Laura, Graef, Elizabeth R. , Jayatilleke, Arundathi , Keen, Helen , Kilian, Adam , Young, Kristen , Cogo, Adriana Karina , Gossec, Laure , Hasseli, Rebecca , Hyrich, Kimme L , Malcata, Armando, Mateus, Elsa F , Schäfer, Martin , Scirè, Carlo Alberto , Sparks, Jeffrey A. , Strangfeld, Anja , Xavier, Ricardo Machado , Bhana, Suleman , Gore‐Massy, Monique , Hausmann, Jonathan S. , Sirotich, Emily , Sufka, Paul , Wallace, Zach, Machado, Pedro , Grainger, Rebecca , Ware, Anna , Gianfrancesco, Milena A , Conway, Richard , Durcan, Laura , Graef, Elizabeth R , Jayatilleke, Arundathi , Keen, Helen , Kilian, Adam , Young, Kristen J , Carmona, Loreto , Cogo, Adriana Karina , Duarte-García, Alí , Gossec, Laure , Hasseli, Rebecca , Hyrich, Kimme L , Langlois, Vincent , Lawson-Tovey, Saskia , Schaefer, Martin , Scirè, Carlo Alberto , Sigurdardottir, Valgerdur , Sparks, Jeffrey A , Xavier, Ricardo M , Bhana, Suleman , Hausmann, Jonathan S , Liew, Jean , Sirotich, Emily , Sufka, Paul , Wallace, Zachary S , Machado, Pedro M , Yazdany, Jinoos , Grainger, Rebecca , Robinson, Philip C , Strangfeld, Anja , Mateus, Elsa F , Carmona, Loreto , Duarte‐García, Alí , Lawson‐Tovey, Saskia , Liew, Jean W. , Yazdany, Jinoos , Robinson, Philip C.

Mayo Clinic

ACR Open Rheumatology | August 24, 2022 | Volume: 4 | Issue: 11 | Pages: 948-953

10.1002/acr2.11495 | PMID 36000538 Get It

ObjectiveTo describe people with gout who were diagnosed with coronavirus disease 2019 (COVID‐19) and hospitalized and to characterize their outcomes.MethodsData on patients with gout hospitalized for COVID‐19 between March 12, 2020, and October 25, 2021, were extracted from the COVID‐19 Global Rheumatology Alliance registry. Descriptive statistics were used to describe the demographics, comorbidities, medication exposures, and COVID‐19 outcomes including oxygenation or ventilation support and death.ResultsOne hundred sixty‐three patients with gout who developed COVID‐19 and were hospitalized were included. The mean age was 63 years, and 85% were male. The majority of the group lived in the Western Pacific Region (35%) and North America (18%). Nearly half (46%) had two or more comorbidities, with hypertension (56%), cardiovascular disease (28%), diabetes mellitus (26%), chronic kidney disease (25%), and obesity (23%) being the most common. Glucocorticoids and colchicine were used pre‐COVID‐19 in 11% and 12% of the cohort, respectively. Over two thirds (68%) of the cohort required supplemental oxygen or ventilatory support during hospitalization. COVID‐19‐related death was reported in 16% of the overall cohort, with 73% of deaths documented in people with two or more comorbidities.ConclusionThis cohort of people with gout and COVID‐19 who were hospitalized had high frequencies of ventilatory support and death. This suggests that patients with gout who were hospitalized for COVID‐19 may be at risk of poor outcomes, perhaps related to known risk factors for poor outcomes, such as age and presence of comorbidity.
The lonidamine derivative H2-gamendazole reduces cyst formation in polycystic kidney disease
Sundar, Shirin V., Zhou, Julie , Magenheimer, Brenda S., Reif, Gail A. , Georg, Gunda I. , Jakkaraj, Sudhakar , Tash, Joseph S. , Yu, Alan S.L. , Calvet, James P. , Zhou, Julie Xia, Wallace, Darren P , Yu, Alan S L , Li, Xiaogang , Calvet, James P , Wallace, Darren P. , Li, Xiaogang

Mayo Clinic

American Journal of Physiology-Renal Physiology | August 18, 2022 | Volume: 323 | Issue: 4 | Pages: F492-F506

10.1152/ajprenal.00095.2022 | PMID 35979967 Get It

Autosomal dominant polycystic kidney disease (ADPKD) is a renal neoplastic disorder characterized by the formation of large fluid-filled cysts that develop from kidney tubules through abnormal cell proliferation and cyst-filling fluid secretion driven by cAMP-dependent Cl − secretion. This study shows that the lonidamine derivative H2-GMZ inhibits Cl − secretion, cell proliferation, and cyst growth, suggesting that it might have therapeutic value for the treatment of ADPKD.
Post-EMR for colorectal polyps, thermal ablation of defects reduces adenoma recurrence: A meta-analysis
Kandel, Pujan , Yadav, Deepesh , Dhungana, Santosh, Brahmbhatt, Bhaumik , Lukens, Frank , Bachuwa, Ghassan , Wallace, Michael B. , Raimondo, Massimo , Lukens, Frank J., Wallace, Michael B , Hussain, Murtaza Shabbir

Mayo Clinic

Endoscopy International Open | August 11, 2022 | Volume: 10 | Issue: 10 | Pages: E1399-E1405

10.1055/a-1922-7646 | PMID 36262518 Get It

Abstract Background and study aims Adenoma recurrence is one of the key limitations of endoscopic mucosal resection (EMR), which occurs in 15 % to 30 % of cases during first surveillance colonoscopy. The main hypothesis behind adenoma recurrence is leftover micro-adenomas at the margins of post-EMR defects. In this systematic review and meta-analysis, we evaluated the efficacy of snare tip soft coagulation (STSC) at the margins of mucosal defects to reduce adenoma recurrence and bleeding complications. Methods Electronic databases such as PubMed and the Cochrane library were used for systematic literature search. Studies with polyps only resected by piecemeal EMR and active treatment: with STSC, comparator: non-STSC were included. A random effects model was used to calculate the summary of risk ratio and 95 % confidence intervals. The main outcome of the study was to compare the effect of STSC versus non-STSC with respect to adenoma recurrence at first surveillance colonoscopy after thermal ablation of post-EMR defects. Results Five studies were included in the systematic review and meta-analysis. The total number patients who completed first surveillance colonoscopy (SC1) in the STSC group was 534 and in the non-STSC group was 514. The pooled adenoma recurrence rate was 6 % (37 of 534 cases) in the STSC arm and 22 % (115 of 514 cases) in the non-STSC arm, (odds ratio [OR] 0.26, 95 % confidence interval [CI], 0.16–0.41, P = 0.001). The pooled delayed post-EMR bleeding rate 19 % (67 of 343) in the STSC arm and 22 % (78 of 341) in the non-STSC arm (OR 0.82, 95 %CI, 0.57–1.18). Conclusions Thermal ablation of post-EMR defects significantly reduces adenoma recurrence at first surveillance colonoscopy.
Development of a Prediction Model for COVID‐19 Acute Respiratory Distress Syndrome in Patients With Rheumatic Diseases: Results From the Global Rheumatology Alliance Registry
Izadi, Zara , Aguirre, Alfredo , Hyrich, Kimme L , Gossec, Laure , Carmona, Loreto , Lawson‐Tovey, Saskia , Kearsley‐Fleet, Lianne , Schaefer, Martin, Seet, Andrea M. , Schmajuk, Gabriela , Jacobsohn, Lindsay, Rush, Stephanie, Sparks, Jeffrey A. , Hsu, Tiffany , Gilbert, Emily, Valenzuela-Almada, Maria O , Ugarte‐Gil, Manuel F. , Ribeiro, Sandra Lúcia Euzébio , Marinho, Adriana de Oliveira , Valadares, Lílian David de Azevedo , Hasseli, Rebecca , Richter, Jutta , Schmeiser, Tim , Torres, Alvaro Andres Reyes , Alle, Gelsomina , Saurit, Verónica , Zanetti, Anna , Carrara, Greta , Labreuche, Julien , Barnetche, Thomas , Hérasse, Muriel, Plassart, Samira, Santos, María José , Machado, Pedro , Sirotich, Emily , Hausmann, Jonathan S. , Sufka, Paul , Grainger, Rebecca , Bhana, Suleman , Costello, Wendy, Wallace, Zachary S. , Registry, Global Rheumatology Alliance, Schäfer, Martin , Gianfrancesco, Milena A , Aguirre, Alfredo , Lawson-Tovey, Saskia , Kearsley-Fleet, Lianne , Schaefer, Martin , Schmajuk, Gabriela , Katz, Patricia , Al-Emadi, Samar , Sparks, Jeffrey A , Wise, Leanna M , Duarte-García, Alí , Ribeiro, Sandra Lúcia Euzébio , Pfeil, Alexander , Santos, Maria José , Robinson, Philip C , Machado, Pedro M , Hausmann, Jonathan S , Grainger, Rebecca , Yazdany, Jinoos , Ugarte-Gil, Manuel F , Carmona, Loreto , Gossec, Laure , Hasseli, Rebecca , Hyrich, Kimme L , Sirotich, Emily , Hsu, Tiffany Y-T , Mateus, Elsa F , Strangfeld, Anja , Mateus, Elsa F , Katz, Patricia , Patel, Naomi J , Wise, Leanna , Duarte‐García, Alí , Di Giuseppe, Daniela , Isnardi, Carolina A , Saurit, Verónica , Khaldi-Plassart, Samira , Rodrigues, Ana Maria , Robinson, Philip C. , Liew, Jean W. , Yazdany, Jinoos , Registry, Global Rheumatology Alliance

Mayo Clinic

ACR Open Rheumatology | July 23, 2022 | Volume: 4 | Issue: 10 | Pages: 872-882

10.1002/acr2.11481 | PMID 35869686 Get It

ObjectiveSome patients with rheumatic diseases might be at higher risk for coronavirus disease 2019 (COVID‐19) acute respiratory distress syndrome (ARDS). We aimed to develop a prediction model for COVID‐19 ARDS in this population and to create a simple risk score calculator for use in clinical settings.MethodsData were derived from the COVID‐19 Global Rheumatology Alliance Registry from March 24, 2020, to May 12, 2021. Seven machine learning classifiers were trained on ARDS outcomes using 83 variables obtained at COVID‐19 diagnosis. Predictive performance was assessed in a US test set and was validated in patients from four countries with independent registries using area under the curve (AUC), accuracy, sensitivity, and specificity. A simple risk score calculator was developed using a regression model incorporating the most influential predictors from the best performing classifier.ResultsThe study included 8633 patients from 74 countries, of whom 523 (6%) had ARDS. Gradient boosting had the highest mean AUC (0.78; 95% confidence interval [CI]: 0.67‐0.88) and was considered the top performing classifier. Ten predictors were identified as key risk factors and were included in a regression model. The regression model that predicted ARDS with 71% (95% CI: 61%‐83%) sensitivity in the test set, and with sensitivities ranging from 61% to 80% in countries with independent registries, was used to develop the risk score calculator.ConclusionWe were able to predict ARDS with good sensitivity using information readily available at COVID‐19 diagnosis. The proposed risk score calculator has the potential to guide risk stratification for treatments, such as monoclonal antibodies, that have potential to reduce COVID‐19 disease progression.
Acute pain pathways: protocol for a prospective cohort study
Jeffery, Molly M. , Ahadpour, Mitra , Allen, Summer V. , Araojo, Richardae , Bellolio, Fernanda , Chang, Nancy, Ciaccio, Laura , Emanuel, Lindsay, Fillmore, Jonathan J., Gilbert, Gregg H. , Koussis, Patricia, Lee, Christine , Lipkind, Heather S. , Mallama, Celeste A. , Meyer, Tamra E. , Moncur, Megan, Nuckols, Teryl K. , Pacanowski, Michael , Page, David B. , Papadopoulos, Elektra J., Ritchie, Jessica , Shah, Nilay D. , Soukup, Mat, Clair, Christopher St. , Tamang, Stephen, Torbati, Sam , Wallace, Douglas W. , Zhao, Yueqin, Heckmann, Rebekah, Jeffery, Molly Moore , Allen, Summer , Fillmore, Jonathan, Bellolio, M Fernanda , Fillmore, Jonathan, Lee, Christine H. , Ross, Joseph S.

Mayo Clinic

BMJ Open | July 5, 2022 | Volume: 12 | Issue: 7 | Pages: e058782

10.1136/bmjopen-2021-058782 | PMID 35790333 Get It

Introduction Opioid analgesics are often used to treat moderate-to-severe acute non-cancer pain; however, there is little high-quality evidence to guide clinician prescribing. An essential element to developing evidence-based guidelines is a better understanding of pain management and pain control among individuals experiencing acute pain for various common diagnoses. Methods and analysis This multicentre prospective observational study will recruit 1550 opioid-naïve participants with acute pain seen in diverse clinical settings including primary/urgent care, emergency departments and dental clinics. Participants will be followed for 6 months with the aid of a patient-centred health data aggregating platform that consolidates data from study questionnaires, electronic health record data on healthcare services received, prescription fill data from pharmacies, and activity and sleep data from a Fitbit activity tracker. Participants will be enrolled to represent diverse races and ethnicities and pain conditions, as well as geographical diversity. Data analysis will focus on assessing patients’ patterns of pain and opioid analgesic use, along with other pain treatments; associations between patient and condition characteristics and patient-centred outcomes including resolution of pain, satisfaction with care and long-term use of opioid analgesics; and descriptive analyses of patient management of leftover opioids. Ethics and dissemination This study has received approval from IRBs at each site. Results will be made available to participants, funders, the research community and the public. Trial registration number NCT04509115 .